Immune checkpoint blockade (ICB) therapy based on antibody-mediated blockade of key checkpoint molecules, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), have achieved clinical success in some cancers. Here, PDCD1 is linked to cancer.